CEO Jim Hollingshead highlighted the company’s achievement of $2.1 billion in revenue for 2024, marking a doubling of revenue in just three years. He emphasized the strong demand and adoption of ...
Management raised full-year 2025 total Omnipod revenue growth guidance to a range of 20%-23% and total company revenue growth guidance to 19%-22%. For Q2 2025, total ...
Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed 16.9% to $585.7 million, with international sales up 33.5%. See the seasonal trading ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted ...
Ashley McEvoy, CEO, reported "we closed 2025 with another strong quarter, recording our 10th consecutive year of 20% or greater constant currency revenue growth," citing durable recurring revenue and ...
Insulet Corporation’s PODD rapid commercial expansion of its Omnipod platform is poised to help it grow in the upcoming quarters. The rising adoption of Omnipod 5 also presents a promising growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results